1.07
+0.01(+0.94%)
Currency In USD
Address
9880 Campus Point Drive
San Diego, CA 92121
United States of America
Phone
858 766 9912
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
July 20, 2016
| Name | Title | Pay | Year Born |
| Mr. Zachary Hornby | Chief Executive Officer, President & Director | 879,594 | 1979 |
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer | 614,844 | 1972 |
| Ms. Jessica Oien J.D. | Chief Legal Officer & Corporate Secretary | 0 | 1971 |
| Dr. Peter Krein Ph.D. | Senior Vice President of Precision Medicine | 0 | N/A |
| Ms. Meredith Wesley | Senior Vice President of Talent & Culture | 0 | N/A |
| Dr. James L. Freddo M.D. | Interim Chief Medical Officer | 0 | 1955 |
| Ms. Sara Weymer | Senior Vice President of Clinical Operations | 0 | N/A |
| Ms. Amy Berkley Ph.D. | Senior Vice President of Program Team | 0 | N/A |
| Mr. David Hinkle | Senior Vice President of Finance, Controller & Corporate Treasurer | 0 | 1962 |
| Mr. Anthony Pinkerton Ph.D. | Senior Vice President of Drug Discovery | 0 | N/A |
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.